BOTULINUM TOXIN A

Base Information

• Chemical Name: BOTULINUM TOXIN A
• CAS No.: 93384-43-1
• Molecular Weight: 0
• Mol file: 93384-43-1.mol

Synonyms:AGN 191622;Allergan (toxin);Botox;Botox Cosmetic;Botulin neurotoxin A;Botulin toxin A;Botulinium toxin type A;Botulinum neurotoxin A;Botulinumtoxin;Botulinum toxin A;Botulinum toxin type A;CBTX-A;Dysport;Linurase;NT201;NT 201 (toxin);Nc 224;Nc 270;Neuronox;Oculinum;OnabotulinumtoxinA;Reloxin;Vistabel;Xeomin;

Chemical Property of BOTULINUM TOXIN A

Chemical Property:

• Appearance/Colour: lyophilized powder
• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: −20°C

Purity/Quality:

99%, ^*data from raw suppliers

Botulinum Toxin A from Clostridium botulinum lyophilized powder ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T+, B
• Hazard Codes: T+,B,Xn
• Statements: 26/27/28-36/38-22
• Safety Statements: 26-28-36/37-45

MSDS Files:

Useful:

• Description: Botulism, a disease of the nervous system in animals and humans, was first recorded in Germany in 1735 and was thought to be due to eating a tainted sausage. The name botulism comes from the German ‘botulus’ for sausage. Botulinum toxin (molecular weight of 100 000, consisting of 1300 amino acids) is derived from Clostridium botulinum – an anaerobic spore-forming gram-positive bacterium commonly found in soil. It can affect a wide range of animals, including mammals, fish, and birds. There are seven serological varieties of botulism denoted by the letters A–G. They are structurally similar but antigenically and serologically unique. Only the botulism types A, B, E, and F can cause toxicity in humans. Types C and D can cause toxicity in animals. From 1990 to 2000, the US Centers for Disease Control documented 263 individual cases from 160 foodborne botulism events in the United States; 4% of these resulted in fatality and 103 of these cases occurred in Alaska. They were due to traditional Alaska aboriginal foods, including the ingestion of raw whale fat or muktuk. While the numbers of cases of foodborne botulism and infant botulism are stable, the incidence of wound botulism has increased due to the use of black tar heroin. California has reported the majority of cases of wound botulism associated with tar heroin use.
• Uses: The use of botulinum toxin includes medicinal (e.g., treatment of spastic conditions, hyperhidrosis), cosmetic (removal of wrinkles), or as a potential terrorism agent (e.g., via aerosolization).
• Indications: Botulinum toxin purified neurotoxin complex (Botox) is a purified form of botulinum toxin type A, produced from a culture of Clostridium botulinum. Injection of botulinum toxin into muscle induces paralysis by inhibiting the release of acetylcholine from motor neurons, thereby blocking neuromuscular conduction. It is approved for the treatment of blepharospasm, strabismus, and excessive sweating. Botox is also approved for use in dermatology to induce paralysis of the muscles of facial expression to reverse deep wrinkles. The effect of an individual treatment usually becomes apparent within 3 days and lasts approximately 3 months. The effect may persist for a longer period after a series of treatments because the muscles atrophy. The major adverse effect is temporary loss of function of a muscle required for normal social functioning, as may occur after inadvertent injection of muscles required for smiling or raising the upper eyelids.
• Biological Functions: Botulism is most commonly caused by ingestion of a neurotoxin produced by Clostridium botulinum in improperly canned food. Poisoning may also occur after wound contamination with the organism. Infant botulism may occur when spores of the organism germinate and manufacture the toxin in the intestinal tract of infants. Botulinum toxin works by inhibiting ACh release at all cholinergic synapses. Botulinum toxins are classified into seven antigenically distinct types, A through G. Each consists of a polypeptide chain of about 150,000 daltons. All but one is nicked by trypsin-type enzymes to yield a light and heavy chain linked by a disulfide bridge.One end of the heavy chain mediates binding to the nerve terminal, and the other initiates internalization of the toxin. The light chain produces the intracellular inhibition of ACh release. This involves a Zn-dependent endopeptidase action to cleave synaptic target proteins that control vesicle docking and fusion with the prejunctional membrane.
• Clinical Use: Botulinum toxin is used clinically in the treatment of blepharospasm, writer’s cramp, spasticities of various origins, and rigidity due to extrapyramidal disorders. It is also used to treat gustatory sweating and cosmetically to decrease facial wrinkles. Botulinum toxin A (Botox, Oculinum) injected intramuscularly produces functional denervation that lasts about 3 months. Clinical benefit is seen within 1 to 3 days.Adverse effects range from diplopia and irritation with blepharospasm to muscle weakness with dystonias.